Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis

Rahul Banerjee, Rachael Sexton, Andrew J. Cowan, Aaron S. Rosenberg, Sikander Ailawadhi, S. Vincent Rajkumar, Shaji K Kumar, Angela Dispenzieri, Sagar Lonial, Brian G.M. Durie, Paul G. Richardson, Saad Z Usmani, Antje Hoering, Robert Z Orlowski

Blood blood.2024025939.

https://doi.org/10.1182/blood.2024025939

Published: 2024

Includes: Supplemental data

Journal Articles

Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone (DIPD) As Salvage Therapy in Early Relapsed/Refractory Multiple Myeloma

Anupama Kumar, Aaron S. Rosenberg, Edward D. Ball, Sarah M. Larson, Lindsey Sirianni, Carolyn M. Mulroney, Caitlin L. Costello

Blood (2023) 142 (Supplement 1): 4750.

https://doi.org/10.1182/blood-2023-181091

Published: 2023

Journal Articles

Covalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the Covalent-101 Study

Blood (2023) 142 (Supplement 1): 2916.

https://doi.org/10.1182/blood-2023-173149

Published: 2023

Journal Articles

A Phase I California Cancer Consortium Study of Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin Lymphoma: Updated Results and Immune Correlative Analyses

Blood (2022) 140 (Supplement 1): 9446–9447.

https://doi.org/10.1182/blood-2022-167173

Published: 2022

Journal Articles

Utilization of Autologous HCT in Multiple Myeloma: A Novel Linkage of CIBMTR, Cancer Registry and Hospitalization Data in California

Naseem S Esteghamat, Ann M Brunson, Ted Wun, Aaron S Rosenberg, Julianne J.P. Cooley, Sara J. Schonfeld, Christa L. Meyer, Bryan Valcarcel, Renata Abrahao, Jeffery Auletta, Lindsay M. Morton, Lori Muffly, Theresa H.M. Keegan

Blood (2022) 140 (Supplement 1): 10060–10062.

https://doi.org/10.1182/blood-2022-159776

Published: 2022

Journal Articles

Assessing Time to Diagnosis, End-Organ Damage and Treatment Response in Young Newly Diagnosed Multiple Myeloma Patients

Michelle A. Quan, Kwan-Keat Ang, Joseph M Tuscano, Mehrdad Abedi, Brian A. Jonas, Naseem S Esteghamat, Jeanna L Welborn, Paul R. Kaesberg, Aaron S Rosenberg

Blood (2022) 140 (Supplement 1): 7203–7205.

https://doi.org/10.1182/blood-2022-162959

Published: 2022

Journal Articles

Healthcare Resource Utilization in Acute Myeloid Leukemia Treatments: Hypomethylating Agent + Venetoclax Vs. High Intensity Regimens

Margaret Li Krackeler, Benjamin Moskoff, Tamer Othman, Tali Azenkot, Ryan J. Beechinor, Aaron S Rosenberg, Naseem S Esteghamat, Rasmus T Hoeg, Joseph M Tuscano, Brian A. Jonas

Blood (2022) 140 (Supplement 1): 8926–8928.

https://doi.org/10.1182/blood-2022-167966

Published: 2022

Journal Articles

Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Early Relapsed/Refractory Multiple Myeloma

Anupama Kumar, Aaron S Rosenberg, Michelle Padilla, Nina Shah, Lindsey Sirianni, Lin Liu, Yuwei Cheng, Emily Pittman, Dimitrios Tzachanis, Sarah Larson, Carolyn Mulroney, Edward D. Ball, Caitlin Costello

Blood (2022) 140 (Supplement 1): 4436–4437.

https://doi.org/10.1182/blood-2022-169838

Published: 2022

Journal Articles

Investigating Differences in Treatment (Tx) Patterns and Clinical Characteristics Among Patients (Pts) Diagnosed with Multiple Myeloma (MM) Across Racial Groups

Ashley Saunders, Samantha Slaff, Krishnaveni Subbiah, Tao Gu, Michelle A. Quan, Aaron S Rosenberg

Blood (2022) 140 (Supplement 1): 13252–13253.

https://doi.org/10.1182/blood-2022-158192

Published: 2022

Journal Articles

Investigating Differences in Clinical Outcomes Among Patients (Pts) Diagnosed with Multiple Myeloma (MM) Across Racial Groups

Ashley Saunders, Samantha Slaff, Krishnaveni Subbiah, Tao Gu, Kwan Ang, Aaron S Rosenberg

Blood (2022) 140 (Supplement 1): 13250–13251.

https://doi.org/10.1182/blood-2022-158187

Published: 2022

Journal Articles

A Phase I Study of Uproleselan Combined with Azacitidine and Venetoclax for the Treatment of Older or Unfit Patients with Treatment Naïve Acute Myeloid Leukemia

Brian A. Jonas, Jeanna L Welborn, Naseem S Esteghamat, Rasmus T Hoeg, Aaron S Rosenberg, Laura Molnar, Ashley Linh Dang-Chu, Susan L Stewart, Joseph M Tuscano

Blood (2022) 140 (Supplement 1): 6213–6214.

https://doi.org/10.1182/blood-2022-168126

Published: 2022

Journal Articles

Identifying Multiple Myeloma Patients Using Automated Data Capture from Electronic Medical Records

Aaron S Rosenberg, Albert William Riedl, Michelle A. Quan, Kwan-Keat Ang, Joseph M Tuscano, Naseem S Esteghamat, Brian A. Jonas, John Graff, Matthew Renquist, Joseph Cawood, Jeanna L Welborn, Rasmus T Hoeg, Paul R. Kaesberg, Kent Anderson, Jason Y Adams, Theresa H.M. Keegan

Blood (2022) 140 (Supplement 1): 7929–7931.

https://doi.org/10.1182/blood-2022-165607

Published: 2022

Journal Articles

A Phase II Trial of the Combination of Obinutuzumab, Venetoclax, and Ibrutinib in Patients with Previously Untreated Follicular Lymphoma

Tamer Othman, Aaron S Rosenberg, John Timmerman, Benjamin Heyman, Haifaa Abdulhaq, Joseph M Tuscano

Blood (2022) 140 (Supplement 1): 11954–11955.

https://doi.org/10.1182/blood-2022-164905

Published: 2022

Journal Articles

A Comprehensive Cancer Center Experience with Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Tamer Othman, Benjamin Moskoff, Matthew Tenold, Tali Azenkot, Margaret Krackeler, Samantha C Fisch, Laura A. Potter, Paul R. Kaesberg, Jeanna Welborn, Ted Wun, Naseem Esteghamat, Rasmus T. Hoeg, Aaron S. Rosenberg, Mehrdad Abedi, Joseph Tuscano, Brian A. Jonas

Blood (2021) 138 (Supplement 1): 4394.

https://doi.org/10.1182/blood-2021-149276

Published: 2021

Journal Articles

An Open-Label Phase II Trial of the Combination of Decitabine, SQ Bortezomib and Pegylated Liposomal Doxorubicin for the Treatment of Patients with Relapsed/Refractory Acute Myelogenous Leukemia

Laura A. Potter, Maria Galkin, Aaron S. Rosenberg, Rasmus T. Hoeg, Mehrdad Abedi, Joseph M. Tuscano, Brian A. Jonas

Blood (2021) 138 (Supplement 1): 2352.

https://doi.org/10.1182/blood-2021-147349

Published: 2021

Journal Articles

Second Primary Malignancy Risk Among HIV-Uninfected and HIV-Infected Survivors of Hodgkin Lymphoma: A 30-Year Follow-up Population-Based Study

Renata Abrahao, MD PhD MSc, Ann M Brunson, MS, Justine M. Kahn, MDMSc, Qian Li, MS, Aaron S Rosenberg, MD, Ted Wun, MD, Theresa Keegan, PhD MS

Blood (2020) 136 (Supplement 1): 15–17.

https://doi.org/10.1182/blood-2020-137728

Published: 2020

Journal Articles

Complications in Acute Myeloid Leukemia Inductions Prior to Count Recovery: A Feasibility Study for Outpatient Care at an Academic Center

Christina Poh, MD, Ebaa Alobeidi, MD, Joseph Tuscano, MD, Aaron S Rosenberg, MD, Rasmus T Hoeg, MD, Brian A Jonas, MD PhD

Blood (2020) 136 (Supplement 1): 28.

https://doi.org/10.1182/blood-2020-136333

Published: 2020

Journal Articles

Changes in Second Primary Malignancies (SPM) after Hodgkin Lymphoma over Time in the United States

Amy Steele, BS, Qian Li, MS, Ann M Brunson, MS, Aaron S. Rosenberg, MD, Ted Wun, MD FACP, FRCPA, Theresa H.M. Keegan, PhD MS

Blood (2017) 130 (Supplement 1): 4097.

https://doi.org/10.1182/blood.V130.Suppl_1.4097.4097

Published: 2017

Journal Articles

Survival after Diffuse Large B-Cell Lymphoma Among Children, Adolescents and Young Adults in the Era of Immunotherapy: A Population-Based Study

Renata Abrahao, MD MSc, Raul C. Ribeiro, MD, Li Tao, PhD, Aaron S. Rosenberg, MD, Theresa H.M. Keegan, PhD MS

Blood (2017) 130 (Supplement 1): 4150.

https://doi.org/10.1182/blood.V130.Suppl_1.4150.4150

Published: 2017

Journal Articles

Incidence of Venous Thromboembolism and Impact on Mortality in Patients with Primary CNS Lymphoma: A Population Based Study

Anjlee Mahajan, MD, Ann M Brunson, MS, Theresa H.M. Keegan, PhD MS, Aaron S. Rosenberg, MD, Ted Wun, MD

Blood (2017) 130 (Supplement 1): 754.

https://doi.org/10.1182/blood.V130.Suppl_1.754.754

Published: 2017

NARROW

Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis

Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone (DIPD) As Salvage Therapy in Early Relapsed/Refractory Multiple Myeloma

Covalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the Covalent-101 Study

A Phase I California Cancer Consortium Study of Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin Lymphoma: Updated Results and Immune Correlative Analyses

Utilization of Autologous HCT in Multiple Myeloma: A Novel Linkage of CIBMTR, Cancer Registry and Hospitalization Data in California

Assessing Time to Diagnosis, End-Organ Damage and Treatment Response in Young Newly Diagnosed Multiple Myeloma Patients

Healthcare Resource Utilization in Acute Myeloid Leukemia Treatments: Hypomethylating Agent + Venetoclax Vs. High Intensity Regimens

Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Early Relapsed/Refractory Multiple Myeloma

Investigating Differences in Treatment (Tx) Patterns and Clinical Characteristics Among Patients (Pts) Diagnosed with Multiple Myeloma (MM) Across Racial Groups

Investigating Differences in Clinical Outcomes Among Patients (Pts) Diagnosed with Multiple Myeloma (MM) Across Racial Groups

A Phase I Study of Uproleselan Combined with Azacitidine and Venetoclax for the Treatment of Older or Unfit Patients with Treatment Naïve Acute Myeloid Leukemia

Identifying Multiple Myeloma Patients Using Automated Data Capture from Electronic Medical Records

A Phase II Trial of the Combination of Obinutuzumab, Venetoclax, and Ibrutinib in Patients with Previously Untreated Follicular Lymphoma

A Comprehensive Cancer Center Experience with Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

An Open-Label Phase II Trial of the Combination of Decitabine, SQ Bortezomib and Pegylated Liposomal Doxorubicin for the Treatment of Patients with Relapsed/Refractory Acute Myelogenous Leukemia

Second Primary Malignancy Risk Among HIV-Uninfected and HIV-Infected Survivors of Hodgkin Lymphoma: A 30-Year Follow-up Population-Based Study

Complications in Acute Myeloid Leukemia Inductions Prior to Count Recovery: A Feasibility Study for Outpatient Care at an Academic Center

Changes in Second Primary Malignancies (SPM) after Hodgkin Lymphoma over Time in the United States

Survival after Diffuse Large B-Cell Lymphoma Among Children, Adolescents and Young Adults in the Era of Immunotherapy: A Population-Based Study

Incidence of Venous Thromboembolism and Impact on Mortality in Patients with Primary CNS Lymphoma: A Population Based Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only